---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-037687"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T11:27:41.683934+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly

## Summary
- Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.
- Non-GAAP net loss of $47.3M ($0.25/share) excluding $89.7M in impairment charges.
- Revenue $21.6M, down from $24.8M; R&D expense fell to $30.5M from $107.3M.
- Cash and investments $456.8M; expected to fund operations into mid-2026.
- Regained full rights to rezpegaldesleukin from Eli Lilly; plans Phase 2b atopic dermatitis study.

## SEC filing metadata
- accession: 0001213900-23-037687
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/0001213900-23-037687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/ea178178-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-037687
- JSON: https://secwatch.observer/filing/0001213900-23-037687.json
- Plain text: https://secwatch.observer/filing/0001213900-23-037687.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported first quarter ended March 31, 2023 results: revenue $21.6 million, net income $137.0 million, EPS $0.73 basic and diluted loss per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $21.6 million
  - Net income: $137.0 million
  - EPS: $0.73 basic and diluted loss per share
  - Result: reported results
  source text: to advance our immunology research pipeline with the goal of advancing a new IND candidate next year.” Summary of Financial Results Revenue in the first quarter of 2023 was $21.6 million as compared to $24.8 million in the first quarter of 2022. Total operating costs and expenses in the first quarter of 2023 were $156.3 million as compared to $141.4 million in
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/0001213900-23-037687-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.